Dynorphin B (1-13) (TFA)
(Synonyms: 强啡肽 B (1-13) 三氟乙酸盐) 目录号 : GC35919
Dynorphin B (1-13) TFA 是一种阿片样 κ 受体 (κ-opioid receptor) 激动剂。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dynorphin B (1-13) TFA acts as an agonist on opioid κ-receptor. κ-opioid receptor[1]
Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide. The neurophysiological actions of Dynorphin B (1-13) have been the subject of considerable research effort[1].
[1]. Chavkin C. Dynorphin--still an extraordinarily potent opioid peptide. Mol Pharmacol. 2013 Apr;83(4):729-36.
| Cas No. | SDF | ||
| 别名 | 强啡肽 B (1-13) 三氟乙酸盐 | ||
| 分子式 | C76H116N21F3O19 | 分子量 | 1684.86 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5935 mL | 2.9676 mL | 5.9352 mL |
| 5 mM | 0.1187 mL | 0.5935 mL | 1.187 mL |
| 10 mM | 0.0594 mL | 0.2968 mL | 0.5935 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Comparison of methods for the Fmoc solid-phase synthesis and cleavage of a peptide containing both tryptophan and arginine
Int J Pept Protein Res 1993 Jul;42(1):58-63.PMID:8103765DOI:10.1111/j.1399-3011.1993.tb00350.x
A major side reaction which can occur during the synthesis of Trp-containing peptides is modification of the Trp indole by reactive carbonium ion species released during acidolytic cleavage. [Asn2,Trp4]Dynorphin A-(1-13), a sequence which is very susceptible to Trp modification, was chosen as a model peptide to compare the effectiveness of various methods proposed to minimize Trp modification during Fmoc solid-phase synthesis. The peptide was synthesized with the side chain of Trp unprotected and cleaved by Reagent K [82.5% trifluoroacetic acid (TFA)/5% phenol/5% water/5% thioanisole/2.5% ethanedithiol (EDT)] [King, D.S. et al. (1990) Int. J. Peptide Protein Res. 36, 255-266], Reagent R [90% TFA/5% thioanisole/3% EDT/2% anisole] [Albericio, F. et al. (1990) J. Org. Chem. 55, 3730-3743], TFA containing 20% EDT and 4% water [Riniker, B. & Hartmann, A. (1990) in Peptides: Chemistry, Structure, and Biology (Rivier, J.E. & Marshall, G.R., eds.), pp. 950-952, Escom, Leiden], and TFA containing trialkylsilane, MeOH, and ethylmethyl sulfide [Chan, W.C. & Bycroft, B.W. (1992) in Peptides: Chemistry, Structure, and Biology, Op. cit., pp. 613-614]. Cleavage with Reagent K, Reagent R and TFA containing 20% EDT and 4% water yielded similar results; in addition to the desired peptide, the crude product contained 22-30% of a side product which appeared to result from Trp modification by a Pmc group. Cleavage with the trialkylsilane-containing mixture gave the lowest recovery of the desired peptide and the highest levels of Pmc-containing peptides.(ABSTRACT TRUNCATED AT 250 WORDS)